News Portal

trader32176
Posts: 3571
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Reports Superior Neurogenesis Induction in Animal Model of Viral Induced Cognitive Dysfunction Compared to other Stem Cell Types

Recent Data Suggests Possibility of Using JadiCells™ in Prevention of COVID-19 Associated Neurological Adverse Effects


https://www.prnewswire.com/news-release ... 53123.html


ELK CITY, Idaho, Aug. 11, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today new data and a patent filing describing the superior ability of JadiCell™ adult stem cells to other stem cell types in terms of stimulating production of new brain cells in an animal model of inflammation. The process of producing new brain cells is termed "neurogenesis" and is an active area of research for the Company.

"We saw that increasing doses of double stranded RNA, which mimics viral induced inflammation, was associated with decreased neurogenesis, which is to be expected. Shockingly, out of the stem cells tested, only the JadiCells were capable of stimulating neurogenesis under conditions of inflammation" stated Dr. James Veltmeyer, Chief Medical Officer of the Company. "These data suggest the possibility that JadiCells may be useful not only for patients with acute COVID-19, which we will test in our upcoming clinical trial, but may also have the potential to fight the long-term consequence of this infection."

"We are eager to explore collaborations with other neurological companies. One interesting thing about the filed patent was the embodiment of combining JadiCells with various existing drugs such as oxytocin, human chorionic growth hormone, and SSRIs" said Famela Ramos, Vice President of Business Development for the Company.

In previous studies the Company has demonstrated the superior activity of JadiCell™ to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%1.

"Given we are getting closer to starting our Phase I/II CTE2 and our Phase III COVID trial, the validation that our cells are more potent than other adult stem cells for the brain is very promising" said Timothy Dixon, President and CEO of the Company and co-inventor. "We are enthusiastic about the success of the JadiCells because of the following characteristics: a) long history of safety data; b) what appears to be superior efficacy data as compared to other stem cells in preclinical models; c) low cost of production; and d) promising human data."

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Therapeutic Solutions International Receives FDA Clearance to Initiate Phase III Pivotal Registration Trial for JadiCell™ Universal Donor COVID-19 Therapy
2 Therapeutic Solutions International Completes FDA Requested Studies to Initiate JadiCell™ Chronic Traumatic Encephalopathy (CTE) Clinical Trial

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 3571
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Prepares to Apply for Emergency Use Authorization (EUA) for its FDA Phase III COVID-19 Stem Cell Therapy JadiCell™

Integrated Immunotherapy Company Seeks to Expand Access to Unique "Living Anti-inflammatory" Therapy Which Previously Demonstrated Potent Preclinical and Clinical Results in COVID-19


https://www.prnewswire.com/news-release ... 55728.html


ELK CITY, Idaho, Aug. 16, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today initiation of preparation for filing an Emergency Use Authorization (EUA) to the FDA for JadiCells™ in treatment of COVID-19 associated lung injury.

The EUA is a mechanism that allows FDA to help strengthen the nation's public health protections against threats such as infectious diseases by facilitating the availability and use of medical countermeasures (MCMs) needed during public health emergencies. Under this provision, the FDA may authorize unapproved medical products to be used in an emergency to treat serious or life-threatening diseases or conditions.

"The extremely promising preclinical data we are generating, as well as the previously published double blind FDA clinical trial and most recently, FDA clearance to enter Phase III, strongly supports the rationale to file for Emergency Use Authorization" said Dr. James Veltmeyer, Chief Medical Officer of the Company. "As a practicing physician, myself and my colleagues are eager to begin using these cells and potentially saving lives".

In previous studies the Company has demonstrated the superior activity of JadiCell™ to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, in an FDA double blind clinical trial the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 ICU patients1 under the age of 85. On August 5th, 2021, the FDA granted clearance for initiation of a Phase III pivotal trial using JadiCells to treat COVID-192.

"We are thankful to our Advisory Board, which includes Dr. Francesco Marincola, World Wide Head of Cell Therapy Research for Gilead, and Dr. Santosh Kesari, Principle Investigator on other stem cell trials for COVID-19, for bringing decades of national and international expertise in dealing with regulatory bodies in fast-tracking approval of cellular and gene therapies in helping us to make this monumental decision" said Timothy Dixon, President and CEO of Therapeutic Solutions International. "Given the urgent nature of the ongoing pandemic, and the early suggestions that our cells are effective against the delta variant, we are exploring and pursuing all possible avenues to bring JadiCells to the patients that need them now."

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Umbilical cord mesenchymal stem cells for COVID–19 acute respiratory distress syndrome: A double–blind, phase 1/2a, randomized controlled trial - Lanzoni - 2021 - STEM CELLS Translational Medicine - Wiley Online Library

2 Therapeutic Solutions International Receives FDA Clearance to Initiate Phase III Pivotal Registration Trial for JadiCell™ Universal Donor COVID-19 Therapy (prnewswire.com)

Contact:
ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

https://therapeuticsolutionsint.com/
trader32176
Posts: 3571
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Identifies and Files Patent on Novel Mechanism of Action of Its FDA Phase III Cleared JadiCell™ Treatment of COVID-19 and Delta Variant

Clinical Stage Immunotherapy Company Discloses Novel Synergic Actions Between its "Living Anti-inflammatory" Stem Cell and FDA Cleared Treatment


https://www.prnewswire.com/news-release ... 57756.html


ELK CITY, Idaho, Aug. 18, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today novel data and filing of a patent application describing a unique mechanism of action of its JadiCell™ universal donor stem cell. The Company used an animal model of advanced lung inflammation, designed to replicate Delta Variant infection, to assess the importance of CD73 expressing T cells. It was found that JadiCell™ administration increased the number of these cells in treated animals, and that depletion of these cells resulted in suppression of JadiCell™ activity.

Furthermore, administration of low dose interleukin-2, while alone providing no protection in the current model, potently increased the ability of JadiCells™ to protect from lung inflammation. It was demonstrated that low dose interleukin-2 increased the number of CD73 T cells.

"As a practicing physician I see firsthand the urgent need for novel approaches towards treating advanced stage COVID-19 patients. The effects of JadiCell™ therapy, in my opinion, are second to none," said Dr. James Veltmeyer, Chief Medical Officer of the Company and co-inventor. "It is, however, fundamentally important to know all the possible mechanisms of action of one's therapeutic candidate, and we must always seek new ways of improving it. To my knowledge we are the first company to actually have data combining and FDA cleared drug (interleukin-2) with a cell therapy based approach for COVID-19."

"In my opinion, Therapeutic Solutions International is an extremely unique company due to its concurrent laser focused strategy of advancing its pipeline forward while at the same time performing basic research experiments to understand at a molecular and cellular level how our products are working," said Famela Ramos, Vice President of Business Development. "Through understanding mechanisms, synergies are identified, patents are filed, and the Company develops hard assets which increase our chances of entering into strategic partnerships or commercialization ourselves."

"One of the advantages we have is our broad research interests which provides a basis for cross-fertilization of ideas across disciplines," said Timothy Dixon, President and CEO of the Company and co-inventor. "What we are trying to do in COVID-19 is to specifically dampen certain pathological parts of the immune system. In our cancer programs we try to do the opposite. By having the ability to apply immunology and regenerative medicine to a variety of problems, we learn a "global view" which is key to our ability to rapidly advance our science. And in biotech, science and patents are everything."

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

https://therapeuticsolutionsint.com/v
trader32176
Posts: 3571
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Recruits Pharmaceutical Industry Veteran Dr. Boris Reznik to Accelerate Value Optimization of FDA Cleared Phase III COVID JadiCell™ Clinical Trial

Venvalo Group to Provide Relations, Strategy, and Regulatory Leadership as Immunotherapy Company Advances Development of JadiCell Adult Stem Cell

https://www.prnewswire.com/news-release ... 58885.html


ELK CITY, Idaho, Aug. 19, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today recruitment of Dr. Boris Reznik to the Company's Advisory Board.

Boris Reznik is the Chairman of Venvalo Group, a venture value optimization firm. During his career, Dr. Reznik founded and built technology companies into market leaders and successfully dealt with both Fortune 500 and emerging companies as clients and partners. He has been a lead or co-investor in startups and mid-market firms and has participated in M&A transactions ranging from Millions to Billions. Dr. Reznik has a depth of experience in processes and systems and a unique perspective in the drug and device development world. As the Chairman of BioRASI, a global CRO, he led development of novel therapeutics, from filing INDs to getting approved NDAs, for companies ranging from startups to Big Pharma.

"Timothy Dixon is an exceptional biotechnology leader who has successfully accumulated more than 50 patents and patent applications in the Company, he has retained top notch advisors and collaborators, and now is in the process of developing a Phase III asset which possesses the potential to address one of the major threats to lives all over the world," said Dr. Boris Reznik. "On behalf of Venvalo Group, we are honored to work with the team assembled by Mr. Dixon and to literally work on saving lives."

In previous studies the Company has demonstrated the superior activity of JadiCell™ to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%1.

"I am delighted to welcome Dr. Reznik to our Advisory Board," said Timothy Dixon, President and CEO of the Company. "He brings a unique lifelong experience in forming, capitalizing, developing and exiting life sciences companies. We look forward to benefiting from Dr. Reznik's counsel as we work towards developing personalized therapeutic approaches."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Umbilical cord mesenchymal stem cells for COVID–19 acute respiratory distress syndrome: A double–blind, phase 1/2a, randomized controlled trial - Lanzoni - 2021 - STEM CELLS Translational Medicine - Wiley Online Library

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 3571
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Announces Titan of Industry Dr. Peter Farrell Joins Advisory Board of its Suicide Prevention Spin-Off Campbell Neurosciences

Founder and Chairman of 40 Billion Dollar Market Cap Company to Accelerate "Science-Based" Approach to Prevention of Suicide


https://www.prnewswire.com/news-release ... 59622.html


ELK CITY, Idaho, Aug. 20, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today that Peter C Farrell, PhD, DSc, AM joined the Advisory Board of its Spin-Off Company Campbell Neurosciences.

Campbell Neurosciences is focused on approaching suicide as a biological disorder and has recently reported positive results on the ability of its in-licensed patent pending blood-based Campbell Score® to predict suicidal ideations1.

"It is with great honor that I welcome Dr. Farrell to the Campbell Neurosciences Advisory Board. Dr. Farrell possesses the rare gift of being very business savvy while also being an acknowledged and well published scientist/engineer. It is rare to find one individual with both traits at such a high level," said Kalina O'Connor President and CEO of Campbell Neurosciences. "I look forward to Dr. Farrell's advice and insight as Campbell Neurosciences continues on its path to developing immunology-based diagnostics and therapeutics for suicidal ideations and actions."

Dr. Farrell is the founder and chairman of the board of ResMed (RMD), a NYSE traded company that changes lives with medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. Dr. Farrell also is Chairman of Arcturus, Inc. (ARCT), a NASDAQ-listed leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Dr. Farrell is on the board of trustees of The Scripps Research Institute, as well as a member of the MIT Dean of Engineering Advisory Board and the Executive Council of the Division of Sleep Medicine at Harvard Medical School, of which he was chair during 2011-2013.

"The story of Campbell Neurosciences is scientifically intriguing, since to my knowledge this is the only company that has successfully used a blood-based immunology marker to explore suicidality as a potential mental disorder," said Dr. Farrell. "I commend Ms. O'Connor for her diligence in creating and obtaining funding for the Company, which was named after her mother, Kathleen Campbell, who was a victim of suicide."

"We at Therapeutic Solutions International are extremely pleased to see Ms. O'Connor take Campbell Neurosciences from what originally was a division founded by our Company to what is now an independent spin-off biotech. She subsequently was successful at fund raising, led completion of clinical trials, and now is attracting internationally renowned business leaders as the Company expands in fulfilling its vision of approaching suicide as a biomedical abnormality as opposed to a selfish choice that people make," said Timothy Dixon, President and CEO of Therapeutic Solutions International and Co-Founder of Campbell. "We will support Campbell Neurosciences and Ms. O'Connor in whatever means necessary to achieve the goal of a world without suicide."

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Therapeutic Solutions International Spin-Off Campbell Neurosciences Announces Positive Clinical Trial Results for Campbell Score Blood Based Suicide Prediction | BioSpace

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 3571
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Announces Positive Preclinical Results Using JadiCells™ in Animal Model of Chronic Obstructive Pulmonary Failure (COPD)
Adult Stem Cell FDA Cleared for COVID-19 Phase III Clinical Trial to be Assessed for Treating Multi-Billion Dollar COPD Market


https://www.prnewswire.com/news-release ... 60477.html

ELK CITY, Idaho, Aug. 23, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced new data and a patent filing covering the use of JadiCells™ and various therapeutic combinations for the treatment of COPD. The experiments involved administration of JadiCells™ intravenously in animals treated with elastase, a protein that elicits deterioration of the lungs in a manner similar to what occurs in COPD.

Superior reduction in lung damage was observed in animals receiving JadiCells™ as compared to other clinically used stem cells such as adipose and bone marrow derived mesenchymal stem cells. In addition, JadiCell™ treated animals possessed significantly decreased expression of the inflammatory proteins toll like receptor 4 and increased expression of the anti-inflammatory protein MerTK.

"The potent anti-inflammatory and regenerative effects of the JadiCells™ have been demonstrated in a variety of in vitro and in vivo settings. Given the inflammatory nature of COPD, as well as previous studies showing potential of regenerative approaches in this condition1,2, we examined the potential of these cells to treat an established animal model of COPD," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "Based on the preliminary positive results, as well as what appears to be a unique mechanism of action, we are in the process of continuing our exploration of JadiCells in COPD, which we believe will be the basis for another IND application."

In a double blind, placebo controlled clinical trial, the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%3.

"From a corporate positioning perspective, we are aiming to concurrently capture as much intellectual property as we can while elucidating in as rapid a manner as possible what indications our JadiCells have the best potential for accelerated development," said Famela Ramos, Vice President of Business Development.

"COPD causes tremendous suffering in patients for which currently there are no curative solutions," stated Timothy Dixon, President and CEO of the Company. "We at Therapeutic Solutions International are committed to cautiously exploring this new potential avenue of research in order to advance science for patients and our shareholders."

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Therapeutic Solutions International A placebo-controlled, randomized trial of mesenchymal stem cells in COPD - PubMed (nih.gov)
2 Adipose stem cell treatment in mice attenuates lung and systemic injury induced by cigarette smoking - PubMed (nih.gov)
3 Umbilical cord mesenchymal stem cells for COVID–19 acute respiratory distress syndrome: A double–blind, phase 1/2a, randomized controlled trial - Lanzoni - 2021 - STEM CELLS Translational Medicine - Wiley Online Library

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 3571
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Recruits Internationally Renowned Stem Cell Pioneer Francisco Silva to Scientific Advisory Board

Phase III COVID-19 Adult Stem Cell Company Continues Attracting Key Opinion Leaders in Preparation of Commercialization of JadiCell


https://www.prnewswire.com/news-release ... 63458.html


ELK CITY, Idaho, Aug. 26, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today the recruitment of stem cell pioneer and key opinion leader Francisco Silva to the Company's Scientific Advisory Board. Mr. Silva will join other Key Opinion Leaders such as Dr. Francesco Marincola of Gilead, Dr. Santosh Kesari who performs COVID-19 clinical trials, and Dr. Boris Reznik founder of two Inc 500 companies.

Mr. Silva currently serves as Vice President of Research and Development for the publicly traded company BioRestorative Therapies where he leads the development of clinical stage adult stem cell therapeutics for disc degeneration1,2, currently BRTX-100 is approved for an FDA Phase 2 clinical trial to treat chronic lumbar disc disease. In addition, Mr. Silva discovered and is commercially developing brown fat stem cells3 under BioRestorative's ThermoStemTM program. Mr. Silva helped start and grow several companies in the regenerative medicine space including PrimeGen Biotech, Medistem Inc and Batu Biologics. Mr. Silva has been collaborating with Dr. Thomas Ichim, Director of Therapeutic Solutions International for more than a decade and have 5 peer reviewed papers published together.

"TSOI has a robust therapeutic pipeline and commercialized products in diverse areas ranging from regenerative medicine and tumor immunology to nutraceuticals. Tim Dixon has demonstrated the ability to rapidly advance technologies through the therapeutics development cycle," said Mr. Silva. "I am honored to work with the impressive team at TSOI and look forward to enhancing the lives of patients while building value to shareholders."

"Having met Mr. Silva on numerous occasions and watching his extraordinary talents to perform cutting edge science while concurrently remaining laser focused on commercialization is truly remarkable and much needed in the biotechnology space," stated Famela Ramos, Vice President of Business Development. "Currently Therapeutic Solutions International is in discussions with numerous potential partners for co-development of the JadiCell™ technology and I look forward to leveraging Mr. Silva's deep industry knowledge and relations to help accelerate our current discussions."

In previous studies the Company has demonstrated the superior activity of JadiCell™ to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%4.

"Mr. Silva is the inventor of numerous game-changing technologies in the area of regenerative medicine. Having watched his work at PrimeGen, which was precursor to the Nobel Prize winning iPSC technology, as well as his subsequent co-discovery of two unique stem cell sources, I must say we are blessed to have Mr. Silva join our Team," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "Only through gathering the best of the best and facilitating synergistic dialogue and pooling of resources can we accomplish our Corporate and Life Goal of addressing the medical needs of patients which currently have no therapeutic options."

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Elabd et al. Intra-discal injection of autologous, hypoxic cultured bone marrow-derived mesenchymal stem cells in five patients with chronic lower back pain: a long-term safety and feasibility study. J Transl Med. 2016 Sep 1;14(1):253.
2 Elabd et al. Comparing atmospheric and hypoxic cultured mesenchymal stem cell transcriptome: implication for stem cell therapies targeting intervertebral discs. J Transl Med . 2018 Aug 10;16(1):222.
3 Silva FJ. Metabolically active human brown adipose tissue derived stem cells. Stem Cells . 2014 Feb;32(2):572-81
4 Umbilical cord mesenchymal stem cells for COVID–19 acute respiratory distress syndrome: A double–blind, phase 1/2a, randomized controlled trial - Lanzoni - 2021 - STEM CELLS Translational Medicine - Wiley Online Library

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 3571
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Files Investigational New Drug Application with FDA for Cancer Blood Vessel Targeting Immunotherapy StemVacs-V to Treat Metastatic Breast Cancer

Company Developing FDA Cleared Phase III Cellular Therapy for COVID-19 Aims to Work with Regulators for Ultra-Rapid Clinical Translation


https://www.prnewswire.com/news-release ... 65037.html


ELK CITY, Idaho, Aug. 30, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today filing of an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) to initiate a clinical trial of its StemVacs-V immunotherapy in patients with metastatic breast cancer.

On May 24th, 2021, the Company announced progress in its preclinical experiments supporting the use of the immunotherapy in human trials. Part of the experiments demonstrated superior activity of StemVacs-V to other immune system-based approaches that were cleared by the FDA to literally "choke" tumors to death by blocking their blood supply1.

"I am honored to be leading medical efforts in bringing this game-changing approach to patients with breast cancer," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "The previous efforts to develop an immunotherapy to kill tumor blood vessels have yielded drugs such as Avastin, which despite limitations, possesses multi-billion dollars in annual sales. In my opinion the StemVacs-V approach is superior to others because it induces more potent and more diverse immune responses targeting cancer blood vessels."

"The filing of today's IND is a significant milestone demonstrating the ability of Therapeutic Solutions International to rapidly move a diverse immunotherapy product pipeline through the drug development cycle," said Famela Ramos, Vice President of Business Development. "We anticipate multiple synergies of our developmental efforts as our candidate's advance forward, with our lead candidate having been cleared by the FDA to initiate Phase III clinical trials.

"Through working with our advisors such as Dr. Francesco Marincola, Dr. Santosh Kesari, and Francisco Silva, who have all published on utilization of First-Generation tumor angiogenesis blocking immunotherapies2,3, we anticipate learning from previous experiences and to rapidly move forward in taking this approach to patients," said Timothy Dixon, President and CEO of the Company and co-inventor of the StemVacs platform. "We thank our collaborators who have worked tirelessly to make this IND filing a possibility in such a rapid manner."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Therapeutic Solutions International Optimizes Targeting the "Achilles Heel" of Cancer Using Second Generation Tumor Endothelial Targeting Vaccine StemVacs-V iPSC (prnewswire.com)
2 Safety of targeting tumor endothelial cell antigens | Journal of Translational Medicine | Full Text (biomedcentral.com)
3 Cancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique? | Journal of Translational Medicine | Full Text (biomedcentral.com)

ir@tsoimail.com

SOURCE Therapeutic Solutions International
trader32176
Posts: 3571
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Signs Memorandum of Understanding with Clinical Stage Immunotherapy Company Eutilogics, Inc. to Explore Augmentation of Synergies between StemVacs-V and TAST

Phase III Cell Therapy Company to Leverage Clinical and Immunological Experience of Korean Clinical Developments to Develop Cancer Killing Therapies


https://www.prnewswire.com/news-release ... 70149.html


ELK CITY, Idaho, Sept. 7, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today the signing of a memorandum of understanding with immunotherapy company Eutilogics, Inc., the wholly owned subsidiary of clinical stage Korean company, Eutilex Co., Ltd., based on exploring synergies between technologies of both Companies.

Eutilex has developed an autologous immunotherapy for tumors which unleash the endogenous ability of T cells to selectively kill tumor cells, even in solid tumors, which will be commercially developed in the US by Eutilogics. As the discoverer of CD137 (4-1BB) and AITR receptors, Eutilogics CEO, Dr. Byoung S. Kwon, is an internationally renowned expert of the immune system, and TAST is a globally competitive targeted cell therapy treatment, which is the result of the validation of decades of research and development.

Therapeutic Solutions International has recently filed an Investigational New Drug application for its StemVacs-V tumor-angiogenesis targeting immunotherapy in breast cancer. StemVacs-V has been demonstrated to induce immune responses to kill blood vessels that feed tumors. StemVacs-V has demonstrated superior tumor inhibition in comparison to other blood vessel targeting immunotherapies in animal models.

"Having collaborated with scientists from Therapeutic Solutions International for several years, we are eager to take our work to the next level through this memorandum of understanding formalizing our collaboration," said Dr. Byoung S. Kwon. "Given that Therapeutic Solutions International has synergistic expertise in cell therapy, we hope to advance more treatment options for patients, much faster."

"Eutilex has been a pioneer in creating novel immunotherapies that leverage the unique molecule 4.1 BB, which is one of the keys in creating an optimized T cell response against tumors. We hope to leverage this technology to kill tumor blood vessels, which appear to be more sensitive towards immunologically based targeting," said Timothy Dixon, President and CEO of Therapeutic Solutions International.

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 3571
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Engages Venvalo Group to Oversee JadiCell COVID-19 Phase III Clinical Trial and Emergency Use Authorization (EUA) Process

https://www.prnewswire.com/news-release ... 73258.html


ELK CITY, Idaho, Sept. 10, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today the engagement of Venvalo Group to assist the Company on regulatory, strategic, and implementation aspects of the recently FDA-cleared Phase III clinical trial assessing ability of JadiCells to treat patients with advanced COVID-19.

"I have known Dr. Boris Reznik for many years and have seen first-hand his ability to rapidly grow companies and perform clinical trials in a variety of disease indications including COVID-19," said Dr. Camillo Ricordi, Principal Investigator of the initial clinical trial, whose promising results resulted in the current FDA approval to proceed with a multi-site, Phase III trial. "Being in the middle of the biggest biological threat that our generation has witnessed, I believe it is imperative to work with top quality groups to rapidly complete this trial and bring this new treatment to patients as quickly as possible."

In 2020 Dr. Ricordi led the international team that successfully completed the first FDA approved controlled trial to treat the most severe cases of COVID-19 with stem cell infusions1. The unprecedented results allowed for 100% patient survival at one month in subjects treated who were less than 85 years old, and 91% survival in subjects of all ages, compared to 42% survival in the control group.

"The work of Dr. Ricordi has significantly impacted the field of medicine in areas of Type 1 Diabetes, regenerative medicine, and transplant immunology," stated Dr. Boris Reznik, Chairman of Venvalo Group. "We are proud to work with this Medical Visionary and to perform the most rapid and effective clinical translation of this novel and life-saving technology as soon as we can."

"By leveraging the knowledge gained from the hundreds of clinical trials performed by Dr. Reznik at bioRASI, as well as the unsurpassed innovative abilities of Dr. Ricordi, we are excited to rapidly move forward with the current clinical trial, as well as the Emergency Use Application, which is currently under development," said Timothy Dixon, President and CEO of Therapeutic Solutions International.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Umbilical cord mesenchymal stem cells for COVID–19 acute respiratory distress syndrome: A double–blind, phase 1/2a, randomized controlled trial

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Post Reply